• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TNYA

    Tenaya Therapeutics Inc.

    Subscribe to $TNYA
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: tenayatherapeutics.com

    Peers

    $AXSM
    $BTAI
    $GTHX
    $RLAY
    $SGTX
    $TPST
    $ELYM

    Recent Analyst Ratings for Tenaya Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    6/10/2024Outperform
    William Blair
    11/30/2023$7.00Outperform
    Leerink Partners
    6/15/2022$25.00Buy
    H.C. Wainwright
    8/24/2021Outperform
    Cowen & Co.
    8/24/2021$31.00Overweight
    Morgan Stanley
    8/24/2021$37.00Buy
    Chardan Capital
    8/24/2021$40.00Overweight
    Piper Sandler
    See more ratings

    Tenaya Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

      TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year Circulating Biomarkers and Other Clinical Measures Mostly Remained Stable or Improved from Baseline Tenaya Management to Host a Webcast Conference Call Today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported encouraging

      12/17/24 7:00:00 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

      SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17. Conference Call and Webcast Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register her

      12/16/24 4:30:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Tenaya Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Tenaya Therapeutics Inc.

      10-Q - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      5/7/25 4:27:33 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      5/7/25 4:18:33 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.

      SCHEDULE 13G - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      5/7/25 9:31:20 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      4/18/25 5:07:15 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Tenaya Therapeutics Inc.

      DEFA14A - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      4/17/25 4:08:26 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Tenaya Therapeutics Inc.

      DEF 14A - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      4/17/25 4:05:42 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Tenaya Therapeutics Inc.

      EFFECT - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      4/1/25 12:15:21 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Tenaya Therapeutics Inc.

      8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      3/28/25 4:08:09 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Tenaya Therapeutics Inc.

      S-3 - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      3/21/25 4:10:56 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Tenaya Therapeutics Inc.

      144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      3/10/25 9:40:49 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Tenaya Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Column Group Iii Gp, Lp bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:40 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Goeddel David V bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:15 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Column Group Iii Gp, Lp bought $9,999,999 worth of shares (2,222,222 units at $4.50) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      2/14/24 4:15:53 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goeddel David V bought $9,999,999 worth of shares (2,222,222 units at $4.50) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      2/14/24 4:12:27 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Tenaya Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Tenaya Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights Significant Disease Burden and Unmet Need Among Adults with PKP2-associated ARVC Data Readouts for TN-201 and TN-401 Clinical Programs On Track for the Second Half of 2025 Cash Runway Extended into Second Half of 2026 SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies tha

      5/7/25 4:05:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

      RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients Experience High Burden of Arrhythmias and Severe Disease Progression Despite Standard-of-Care Treatments Large Majority of PKP2-associated ARVC Patients Appear Eligible for TN-401 Gene Therapy Based on Low Rates of Preexisting Immunity to AAV9 Antibodies SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of hea

      4/24/25 2:07:47 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

      TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25 SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart

      3/31/25 10:00:00 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

      SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publications of positive preclinical data for TN-201, the company's gene therapy candidate for Myosin-Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), in Nature Communications. Variants in the MYBPC3 gene resulting in insufficient levels of MyBP-C protein are the most common genetic cause of HCM. TN-201 is Tenaya's adeno-associated virus serotype 9 (AAV9)-based gene therapy

      3/24/25 8:30:00 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

      SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that new clinical and disease burden data pertaining to the company's MYBPC3-associated hypertrophic cardiomyopathy (HCM) program will be presented at the upcoming American College of Cardiology's Annual Scientific Session being held March 29-31, 2025 in Chicago, IL. Tenaya is advancing TN-201, an AAV9-based gene therapy for the potential treatment of MYBPC3-associated HCM, a condition caused by in

      3/19/25 8:30:00 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation at the American College of Cardiology Meeting Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 Recent $48.9 Million Financing Extends Cash Runway into mid-2026 SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies

      3/10/25 4:05:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Announces Pricing of Public Offering

      SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 75,000,000 total units for gross proceeds of approximately $52.5 million prior to deducting underwriting discounts and commissions and offering expenses.  Tenaya intends to use the net proceeds from the offering to fund the ongoing and planned development of its clinical and early-stage product candidates, particularly TN-201 and TN-401, and for work

      3/3/25 11:19:31 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Announces Proposed Public Offering

      SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and Series A warrants and Series B warrants, each to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares of common stock at a purchase price of $0.001 per share, Series A warrants and Series B warrants. The pre-funded warrants

      3/3/25 4:10:10 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

      SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in TD Cowen's 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows: TD Cowen 45th Annual Health Care ConferenceDate: Tuesday, March 4Time: 1:10 PM ET – 1:40 PM ETFormat: Company Presentation Leerink Partners Global Healthcare Conference 2025Date: Wednesday, March 12Ti

      3/3/25 8:00:00 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

      Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies th

      1/13/25 9:16:36 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, Finance Higa Tomohiro sold $1,336 worth of shares (2,482 units at $0.54), decreasing direct ownership by 2% to 99,690 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/10/25 9:44:50 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Tingley Whittemore sold $3,983 worth of shares (7,398 units at $0.54), decreasing direct ownership by 4% to 174,793 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/10/25 9:43:12 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Ali Faraz sold $5,245 worth of shares (9,741 units at $0.54), decreasing direct ownership by 3% to 320,514 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/10/25 9:42:17 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Column Group Iii Gp, Lp bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:40 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Goeddel David V bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:15 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Higa Tomohiro claimed ownership of 102,172 shares (SEC Form 3)

      3 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      2/7/25 8:30:20 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Ali Faraz was granted 141,924 shares, increasing direct ownership by 75% to 330,255 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      2/7/25 8:29:29 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Tingley Whittemore was granted 71,676 shares, increasing direct ownership by 67% to 178,782 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      1/28/25 8:00:12 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, Accounting and Fin. Ops. Saito Chihiro sold $4,787 worth of shares (2,258 units at $2.12), decreasing direct ownership by 4% to 60,983 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      11/18/24 8:48:18 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Walsh Jeffrey T.

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      10/21/24 8:43:46 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Tenaya Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Tenaya Therapeutics

      William Blair initiated coverage of Tenaya Therapeutics with a rating of Outperform

      6/10/24 7:25:34 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Leerink Partners initiated coverage on Tenaya Therapeutics with a new price target

      Leerink Partners initiated coverage of Tenaya Therapeutics with a rating of Outperform and set a new price target of $7.00

      11/30/23 7:50:26 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Tenaya Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $25.00

      6/15/22 7:41:04 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cowen & Co. initiated coverage on Tenaya Therapeutics

      Cowen & Co. initiated coverage of Tenaya Therapeutics with a rating of Outperform

      8/24/21 7:24:12 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley initiated coverage on Tenaya Therapeutics with a new price target

      Morgan Stanley initiated coverage of Tenaya Therapeutics with a rating of Overweight and set a new price target of $31.00

      8/24/21 7:23:09 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital initiated coverage on Tenaya Therapeutics with a new price target

      Chardan Capital initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $37.00

      8/24/21 6:03:25 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Tenaya Therapeutics with a new price target

      Piper Sandler initiated coverage of Tenaya Therapeutics with a rating of Overweight and set a new price target of $40.00

      8/24/21 5:15:10 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Tenaya Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      11/14/24 5:46:12 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      11/14/24 1:22:39 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Tenaya Therapeutics Inc. (Amendment)

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      2/14/24 5:01:36 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Tenaya Therapeutics Inc. (Amendment)

      SC 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      2/14/24 4:19:04 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Tenaya Therapeutics Inc. (Amendment)

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      2/14/24 10:03:04 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Tenaya Therapeutics Inc. (Amendment)

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      2/14/24 7:29:44 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Tenaya Therapeutics Inc.

      SC 13G - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      1/31/24 2:08:26 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Tenaya Therapeutics Inc. (Amendment)

      SC 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      2/21/23 5:26:38 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Tenaya Therapeutics Inc. (Amendment)

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      2/14/23 4:45:47 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Tenaya Therapeutics Inc. (Amendment)

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      2/14/23 12:38:14 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Tenaya Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

      Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance. She is currently the Chief Financial and Business Officer a

      4/26/23 7:00:00 AM ET
      $NKTX
      $TNYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

      SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. "We are pleased to welcome Ms. Burroughs to the Tenaya Board. Her substantial and diverse industry experience in the development and commercia

      12/7/22 4:30:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Provides 2022 Business Updates

      Company announces development candidate selection of its second gene therapy program, TN-401, targeting the leading genetic cause of arrhythmogenic right ventricular cardiomyopathy (gARVC) IND applications for TN-201 and TN-301 (previously named TYA-11631) expected to be submitted in the second half of 2022 Appoints Jennifer Drimmer, J.D., as General Counsel Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today provided a 2022 business update including the selection of TN-401 as the development candidate for the treatment of Genetic Arrhythmogenic

      1/10/22 8:00:00 AM ET
      $EXEL
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture

      Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced the appointments of Karah Parschauer, J.D., to its Board of Directors and of Joanna Auch as Senior Vice President of People and Culture. "Tenaya is at an important inflection point in our growth and maturity. We are now a public company with more than 100 employees who represent our commitment to internalize critical capabilities, including cGMP manufacturing and clinical development," said Faraz Ali, CEO of Tenaya. "Both Karah and Joanna are strong leaders who bring highly relevant strategic

      12/22/21 4:05:00 PM ET
      $ANEB
      $EOLS
      $TNYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)